(R)-Crizotinib – 50 mg

Brand:
Cayman
CAS:
877399-52-5
Storage:
-20
UN-No:
De Minimis - 3077 / 9

(R)-Crizotinib is a derivative of aminopyridine that acts as a potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC50 = 8 nM) and ALK (IC50 = 20 nM) receptor tyrosine kinases.{22302} (R)-Crizotinib shows antitumor efficacy, including cytoreductive antitumor activity, in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC50s = 5-20 nM).{22302,22301} (R)-Crizotinib is currently undergoing active clinical investigation in non-small cell lung cancer and phase I/II studies are being conducted in patients with anaplastic large cell lymphoma or neuroblastoma.{22301,20554}  

 

Available on backorder

SKU: 12087 - 50 mg Category:

Description

A potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC50 = 8 nM) and ALK (IC50 = 20 nM) receptor tyrosine kinases; shows antitumor efficacy in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC50s = 5-20 nM)


Formal name: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine

Synonyms:  PF 2341066

Molecular weight: 450.3

CAS: 877399-52-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling